How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
Find Out in this Research Report.
John Temperato, insider at 9 Meters Biopharma

John Temperato Insider Information

Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience.

What is John Temperato's net worth?

The estimated net worth of John Temperato is at least $375,438.29 as of July 6th, 2022. Mr. Temperato owns 1,427,522 shares of 9 Meters Biopharma stock worth more than $375,438 as of August 11th. This net worth approximation does not reflect any other investments that Mr. Temperato may own. Additionally, Mr. Temperato receives a salary of $751,940.00 as CEO at 9 Meters Biopharma. Learn More about John Temperato's net worth.

How old is John Temperato?

Mr. Temperato is currently 57 years old. There are 2 older executives and no younger executives at 9 Meters Biopharma. Learn More on John Temperato's age.

What is John Temperato's salary?

As the CEO of 9 Meters Biopharma, Inc., Mr. Temperato earned a total compensation package of $1,013,869.00 in 2021. Mr. Temperato earned a salary of $371,500.00, options awards of $523,489.00, non-equity compensation of $118,880.00, and no other miscellaneous compensation. Learn More on John Temperato's salary.

How do I contact John Temperato?

The corporate mailing address for Mr. Temperato and other 9 Meters Biopharma executives is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. 9 Meters Biopharma can also be reached via phone at (919) 275-1933 and via email at [email protected] Learn More on John Temperato's contact information.

Has John Temperato been buying or selling shares of 9 Meters Biopharma?

During the last ninety days, John Temperato has bought $28,750.00 of 9 Meters Biopharma stock. Most recently, on Wednesday, July 6th, John Temperato bought 125,000 shares of 9 Meters Biopharma stock. The stock was acquired at an average cost of $0.23 per share, with a total value of $28,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,427,522 shares of the company's stock, valued at $328,330.06. Learn More on John Temperato's trading history.

Who are 9 Meters Biopharma's active insiders?

9 Meters Biopharma's insider roster includes Michael Constantino (Director), Mark Sirgo (Director), Edward Sitar (CFO), and John Temperato (CEO). Learn More on 9 Meters Biopharma's active insiders.

Are insiders buying or selling shares of 9 Meters Biopharma?

In the last twelve months, 9 Meters Biopharma insiders bought shares 12 times. They purchased a total of 762,979 shares worth more than $489,410.44. The most recent insider tranaction occured on July, 6th when CEO John Temperato bought 125,000 shares worth more than $28,750.00. Insiders at 9 Meters Biopharma own 2.4 % of the company. Learn More about insider trades at 9 Meters Biopharma.

Information on this page was last updated on 7/6/2022.

John Temperato Insider Trading History at 9 Meters Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/6/2022Buy125,000$0.23$28,750.001,427,522View SEC Filing Icon  
3/3/2022Buy100,000$0.56$56,000.00View SEC Filing Icon  
11/18/2021Buy50,000$1.05$52,500.00View SEC Filing Icon  
8/18/2021Buy25,000$1.05$26,250.001,102,522View SEC Filing Icon  
4/5/2021Buy100,000$1.00$100,000.001,077,522View SEC Filing Icon  
8/21/2020Buy70,000$0.69$48,300.00615,496View SEC Filing Icon  
8/17/2020Buy35,000$0.57$19,950.00545,496View SEC Filing Icon  
6/15/2020Buy10,000$0.60$6,000.00
See Full Table

John Temperato Buying and Selling Activity at 9 Meters Biopharma

This chart shows John Temperato's buying and selling at 9 Meters Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

9 Meters Biopharma Company Overview

9 Meters Biopharma logo
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Read More

Today's Range

Now: $0.26
Low: $0.26
High: $0.27

50 Day Range

MA: $0.34
Low: $0.21
High: $0.64

2 Week Range

Now: $0.26
Low: $0.20
High: $1.46

Volume

55,460 shs

Average Volume

2,602,151 shs

Market Capitalization

$68.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo?
Communist China has the USA in a resource stranglehold. They have a monopoly on this CRITICAL metal that we desperately need for military technology. In fact, both Trump AND Biden passed executive orders that addressed this crisis. And it could have a massive effect on smart investor's bank accounts.
See This Growing National Security Threat Here